Who are NuTRIflex Lipid peri's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intradialytic parenteral nutrition, Nutriflex Omega special + Oxepa, All-in-one parenteral nutrition.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nutriflex-lipid-peri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

NuTRIflex Lipid peri — Competitive Intelligence Brief

NuTRIflex Lipid peri (NuTRIflex Lipid peri) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Parenteral nutrition formulation. Area: Nutritional support / Critical care.

phase 3 Parenteral nutrition formulation Nutritional support / Critical care Small molecule Live · refreshed every 30 min

Target snapshot

NuTRIflex Lipid peri (NuTRIflex Lipid peri) — B. Braun Melsungen AG. NuTRIflex Lipid peri is a parenteral nutrition emulsion that provides essential lipids, amino acids, and other nutrients for perioperative nutritional support in patients unable to eat normally.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
NuTRIflex Lipid peri TARGET	NuTRIflex Lipid peri	B. Braun Melsungen AG	phase 3	Parenteral nutrition formulation
Intradialytic parenteral nutrition	Intradialytic parenteral nutrition	EZUS-LYON 1	marketed	Nutritional supplement / parenteral nutrition formulation
Nutriflex Omega special + Oxepa	Nutriflex Omega special + Oxepa	B. Braun Melsungen AG	phase 3	Parenteral nutrition formulation
All-in-one parenteral nutrition	All-in-one parenteral nutrition	Fujian Shengdi Pharmaceutical Co., Ltd.	phase 3	Parenteral nutrition formulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Parenteral nutrition formulation class)

B. Braun Melsungen AG · 2 drugs in this class
Fujian Shengdi Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NuTRIflex Lipid peri — Competitive Intelligence Brief. https://druglandscape.com/ci/nutriflex-lipid-peri. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab